Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
... risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's ...
Read the original at FirstWord Pharma ↗
- Topics
- Copyright & IPRegulation & PolicyMarkets & InvestmentLegal & Courts
- Tracked via
- “AI Risks”